RHCG and Familial prostate cancer: Finally, a 2-gene panel comprising RHCG and TCAF1 methylation was developed in the training cohort (203 Danish prostate cancer patients) and successfully validated in the validation cohort (286 Swiss/American prostate cancer patients) where it added significant independent prognostic value to routine clinicopathological parameters.